Perceptive Advisors LLC Files Schedule 13G for Travere Therapeutics, Inc.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., filed a Schedule 13G with the SEC on October 14, 2025, disclosing beneficial ownership of 4,895,615 shares of Common Stock in Travere Therapeutics, Inc. This represents a 5.5% ownership stake in the company. The filing indicates that the shares are held by the Master Fund, with Perceptive Advisors serving as the investment manager and Joseph Edelman as the managing member. The filing certifies that the shares were not acquired for the purpose of influencing the control of the issuer. The event date requiring this filing was October 6, 2025.